Search Results - "Haight, Paulina"

Targeted Therapies in Low-Grade Serous Ovarian Cancers by Gonzalez, Anna, Nagel, Christa I., Haight, Paulina J.

“…Opinion Statement Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the…”
Get full text

“More than a song and dance”: Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok by Morton, Molly, Haight, Paulina J., Khadraoui, Wafa, Backes, Floor, Bixel, Kristin, O'Malley, David M., Nagel, Christa, Chambers, Laura M.

“…To investigate themes, quality, and reliability of gynecologic cancer-related content on the social media application TikTok. TikTok was systematically…”
Get full text

The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria by Haight, Paulina J., Riedinger, Courtney J., Backes, Floor J., O'Malley, David M., Cosgrove, Casey M.

“…We sought to provide a contemporary report on stage IVB endometrial carcinoma (2009 FIGO criteria) and applied the 2023 FIGO staging criteria to this…”
Get full text

Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis by Barrington, David A., Riedinger, Courtney, Haight, Paulina J., Tubbs, Crystal, Cohn, David E.

“…To determine the cost-effectiveness of the addition of pembrolizumab in various combinations in patients with recurrent/metastatic cervical cancer. A…”
Get full text

Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens? by Haight, Paulina J., Lammers, Sydney, Kistenfeger, Quinn, Leipold, Chelsea, Suarez, Adrian A., Tozbikian, Gary H., Esnakula, Ashwini, Cosgrove, Casey, Bixel, Kristin L.

“…The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) recommend cold ischemia time (cIT) be <60 min, and formalin fixation…”
Get full text

Characterization of mismatch‐repair/microsatellite instability‐discordant endometrial cancers by Riedinger, Courtney J., Esnakula, Ashwini, Haight, Paulina J., Suarez, Adrian A., Chen, Wei, Gillespie, Jessica, Villacres, Alyssa, Chassen, Alexis, Cohn, David E., Goodfellow, Paul J., Cosgrove, Casey M.

“…Background Mismatch‐repair (MMR)/microsatellite instability (MSI) status has therapeutic implications in endometrial cancer (EC). The authors evaluated the…”
Get full text

Authentic leadership in action: Experience gained from a gynecologic oncology fellowship leadership curriculum by Levine, Monica D., Wagner, Vincent M., Riedinger, Courtney J., Khadraoui, Wafa, Haight, Paulina J., Morton, Molly, Cohn, David E.

“…•Leadership in medicine(and in gynecologic oncology) is multifaceted and underemphasized in traditional education.•Leaders within gynecologic oncology have…”
Get full text

Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis by Barrington, David A., Haight, Paulina J., Calhoun, Cody, Tubbs, Crystal, Cohn, David E., Bixel, Kristin L.

“…To determine the cost-effectiveness of lenvatinib plus pembrolizumab (LP) in patients with microsatellite stable (MSS), recurrent, pretreated endometrial…”
Get full text

Reply to “Mismatch repair and microsatellite instability—Recommendation for an optimal test strategy” by Riedinger, Courtney J., Esnakula, Ashwini, Haight, Paulina J., Suarez, Adrian A., Chen, Wei, Gillespie, Jessica, Villacres, Alyssa, Chassen, Alexis, Cohn, David E., Goodfellow, Paul J., Cosgrove, Casey M.

Get full text

Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer by Riedinger, Courtney J, Barrington, David A, Nagel, Christa I, Khadraoui, Wafa K, Haight, Paulina J, Tubbs, Crystal, Backes, Floor J, Cohn, David E, O'Malley, David M, Copeland, Larry J, Chambers, Laura M

“…The combination of dostarlimab with carboplatin and paclitaxel has demonstrated improved progression-free survival (PFS) and overall survival (OS) in primary…”
Get full text

Retraction notice to “Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer” [Gynecologic Oncology 183 (2024) 78–84] by Riedinger, Courtney J., Barrington, David A., Nagel, Christa I., Khadraoui, Wafa K., Haight, Paulina J., Tubbs, Crystal, Backes, Floor J., Cohn, David E., O'Malley, David M., Copeland, Larry J., Chambers, Laura M.

Get full text

RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer by Riedinger, Courtney J., Barrington, David A., Nagel, Christa I., Khadraoui, Wafa K., Haight, Paulina J., Tubbs, Crystal, Backes, Floor J., Cohn, David E., O'Malley, David M., Copeland, Larry J., Chambers, Laura M.

“…This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal). This article…”
Get full text

Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer by Riedinger, Courtney J, Brown, Morgan, Haight, Paulina J, Backes, Floor J, Cohn, David E, Goodfellow, Paul J, Cosgrove, Casey M

“…We sought to evaluate the contribution of mismatch repair (MMR) status to traditional risk stratification algorithms used to predict nodal involvement and…”
Get full text

The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer by Haight, Paulina J., Kistenfeger, Quinn, Riedinger, Courtney J., Khadraoui, Wafa, Backes, Floor J., Bixel, Kristin L., Copeland, Larry J., Cohn, David E., Cosgrove, Casey M., O'Malley, David M., Nagel, Christa I., Spakowicz, Daniel J., Chambers, Laura M.

“…We sought to assess the impact of antibiotic (ABX) and proton-pump inhibitor (PPI) use on progression-free (PFS) and overall survival (OS) in patients treated…”
Get full text

Recurrent malignant struma ovarii presenting as peritoneal carcinomatosis in the setting of an intact thyroid: A case report and review of the literature by Brown, Morgan, Haight, Paulina, Ringel, Matthew, Phay, John, Esnakula, Ashwini, Vazzano, Jennifer, Cosgrove, Casey

“…•Malignant struma ovarii is rare and without established criteria regarding management and surveillance.•Many authors have supported stratification of…”
Get full text

Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population by Haight, Paulina J., Barrington, David A., Graves, Stephen M., Piver, Rachael N., Baek, Jae, Ardizzone, Melissa, Akinduro, Jenifer A., Busho, Audrey C., Fadoju, Deborah, Pandit, Radhika, Stephens, Raeshawn, Strowder, Lauren M., Tadepalli, Shreekari, VanNoy, Brianna, Sriram, Bhargavi, McLaughlin, Eric M., Lightfoot, Michelle D.S., Bixel, Kristin L., Cohn, David E., Cosgrove, Casey M., O'Malley, David, Salani, Ritu, Nagel, Christa I., Backes, Floor J.

“…To determine whether morbid obesity should serve as an independent factor in the decision for same day discharge following minimally invasive hysterectomy…”
Get full text

The poor prognosis of sarcomatoid carcinoma arising from low grade serous ovarian cancer: A case report and review of the literature by Haight, Paulina, Savage, Johanna, Bixel, Kristin

“…•Sarcomatoid or anaplastic carcinomas arising within serous ovarian neoplasms are rare.•Despite small size, sarcomatoid carcinomas are aggressive spindle cell…”
Get full text

Learning to lead: The evolution of a pilot leadership curriculum for gynecologic oncology fellows at the Ohio State University by Levine, Monica D., Wagner, Vincent M., Riedinger, Courtney J., Khadraoui, Wafa, Haight, Paulina J., Morton, Molly, Barrington, David A., Calo, Corinne A., Castaneda, Antonio V., Lightfoot, Michelle, Chalif, Julia, Gonzalez, Anna, Cohn, David E.

“…•Leadership training is under-emphasized in traditional medical education.•An effective leadership curriculum must be dynamic and requires genuine investment…”
Get full text

Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II? by Levine, Monica D., O'Malley, David M., Haight, Paulina J., Senter, Leigha, Wagner, Vincent, Bixel, Kristin L., Cohn, David E., Copeland, Larry J., Cosgrove, Casey M., McLaughlin, Eric M., Backes, Floor J.

“…•Despite a high rate of complete surgical staging and six cycles of adjuvant chemotherapy, the risk of recurrence was 37%.•Recurrence rate was higher for…”
Get full text

Lateral thoracotomy for epicardial pacemaker placement in patients with congenital heart disease by Haight, Paulina J, Stewart, Robert E, Saarel, Elizabeth V, Pettersson, Gosta B, Najm, Hani K, Aziz, Peter F

“…Abstract OBJECTIVES Our institution adopted a lateral thoracotomy approach to epicaridal pacemaker implantation with the objective of avoiding epicardial scar…”
Get full text